Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Box 0018-7, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.
Nat Rev Cancer. 2011 Oct 24;11(11):805-12. doi: 10.1038/nrc3153.
The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provideclinical benefit are not completely understood. However, knowledge of these mechanisms will be crucial for probing human immune responses and tumour biology in order to understand what distinguishes responders from non-responders. The following next steps are necessary: first, the development of immune-monitoring strategies for the identification of relevant biomarkers; second, the establishment of guidelines for the assessment of clinical end points; and third, the evaluation of combination therapy strategies to improve clinical benefit.
美国食品和药物管理局（FDA）最近批准了两种新型免疫治疗药物，sipuleucel-T 和 ipilimumab，分别显示出对转移性前列腺癌和黑色素瘤患者的生存益处。这些药物提供临床益处的机制尚不完全清楚。然而，了解这些机制对于探究人类免疫反应和肿瘤生物学以了解区分应答者和非应答者的因素至关重要。以下是必要的下一步：首先，开发免疫监测策略以识别相关生物标志物；其次，建立评估临床终点的指南；最后，评估联合治疗策略以提高临床获益。
